title: Intravitreal Bevacizumab and Ranibizumab in the Treatment of Acute Central Serous Chorioretihopathy: A Single Center Retrospective Study.
abstract: OBJECTIVE
  To evaluate and compare the anatomical and functional outcomes of patients with acute central serous chorioretinopathy (CSC) who did not receive any intervention or treatment with intravitreal bevacizumab or ranibizumab.
  
  
  METHODS
  A single-center retrospective comparative study. Seventy eyes of 70 patients were recruited for the study; 27 patients were only observed without any medication or intervention (observation group), 23 were treated with intravitreal bevacizumab (IVB group), and the remaining 20 were treated with intavitreal ranibizumab (IVR group). The best-corrected visual acuity (BCVA) and central macular thickness (CMT) obtained by spectral-domain optical coherence tomography were compared between the groups.
  
  
  RESULTS
  There were no significant differences between the groups with regard to age, sex, and follow-up periods (p>0.05). The mean time from baseline to initial complete resolution of subretinal fluid was 3.52±1.64 months in the observation group, 1.19±0.60 months in the IVB group, and 1.11±0.47 months in the IVR group; the resolution time was significantly longer in the observation group (p<0.001). While the CMT was significantly thicker in the observation group when compared to the IVB and IVR groups in the first month (p=0.001), it was similar between the groups in the third, sixth, and twelfth months (p>0.05). Additionally, pairwise comparisons of the IVB and IVR groups revealed that there were no significant differences between these groups regarding CMT at any follow-up time (p>0.05).
  
  
  CONCLUSIONS
  Compared with observation alone, neither IVB nor IVR had a positive effect in terms of anatomical and functional outcomes for acute CSC. Although the resolution time of SRF is shorter by using ranibizumab, both the ranibizumab and bevacizumab could be effective in achieving rapid resolution of serous detachment in patients with acute CSC.
authors.affiliation: a Ankara Ulucanlar Eye Training and Research Hospital , Ankara , Turkey.
authors.forename: Kemal
authors.identifier: http://orcid.org/0000-0002-7461-6129
authors.initials: K
authors.lastname: Tekin
authors.affiliation: a Ankara Ulucanlar Eye Training and Research Hospital , Ankara , Turkey.
authors.forename: Mehmet Ali
authors.initials: MA
authors.lastname: Sekeroglu
authors.affiliation: b Ophthalmology Department , Hacettepe University , Ankara , Turkey.
authors.forename: Ali Bulent
authors.initials: AB
authors.lastname: Cankaya
authors.affiliation: a Ankara Ulucanlar Eye Training and Research Hospital , Ankara , Turkey.
authors.forename: Mehmet Yasin
authors.initials: MY
authors.lastname: Teke
authors.affiliation: a Ankara Ulucanlar Eye Training and Research Hospital , Ankara , Turkey.
authors.forename: Sibel
authors.initials: S
authors.lastname: Doguizi
authors.affiliation: a Ankara Ulucanlar Eye Training and Research Hospital , Ankara , Turkey.
authors.forename: Pelin
authors.initials: P
authors.lastname: Yilmazbas
mesh_terms: D000208:Acute Disease; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D056833:Central Serous Chorioretinopathy / Q000175:diagnosis / Q000188:drug therapy*; D002829:Choroid / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab / Q000008:administration & dosage*; D012160:Retina / Q000473:pathology*; D012189:Retrospective Studies; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab
keywords: Central macular thickness; central serous chorioretinopathy; intravitreal bevacizumab; intravitreal ranibizumab; vascular endothelial growth factor